Review

ginsenoside rb1 (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress ginsenoside rb1
Ginsenoside Rb1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 19 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ginsenoside+rb1/pmc13121073-23-0-17?v=MedChemExpress
Average 95 stars, based on 19 article reviews

ginsenoside rb1 - by Bioz Stars, 2026-08

95/100 stars

Images

Image Search Results

Design strategy and the fabrication process of GRb1@LEVS-cRGD and its therapeutic effects on ALI. (a) The hybrid vesicle was constructed through fusion of lemon derived vesicles (LEVs) and nanosized ginsenoside Rb1 (GRb1). Subsequently, GRb1@LEVS-cRGD were fabricated by modifying Chol-PEG 2000 -cRGD onto the surface of GRb1@LEVs using a membrane insertion technique. Antibiotics TIG and Vanc was sequentially encapsulated via remote loading to produce TIG/GRb1@LEVS-cRGD and Vanc/GRb1@LEVS-cRGD, respectively. (b) In vivo , GRb1@LEVS-cRGD markedly attenuated the production of inflammatory mediators, suppressed pulmonary inflammation, and mitigated lung tissue damage. Antibiotic-loaded GRb1@LEVS-cRGD effectively reached the infection sites and exhibited both anti-inflammatory and synergistic bactericidal effects. (c) Cytoprotective Capacity of GRb1@LEVs-cRGD in inflammation.

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: Design strategy and the fabrication process of GRb1@LEVS-cRGD and its therapeutic effects on ALI. (a) The hybrid vesicle was constructed through fusion of lemon derived vesicles (LEVs) and nanosized ginsenoside Rb1 (GRb1). Subsequently, GRb1@LEVS-cRGD were fabricated by modifying Chol-PEG 2000 -cRGD onto the surface of GRb1@LEVs using a membrane insertion technique. Antibiotics TIG and Vanc was sequentially encapsulated via remote loading to produce TIG/GRb1@LEVS-cRGD and Vanc/GRb1@LEVS-cRGD, respectively. (b) In vivo , GRb1@LEVS-cRGD markedly attenuated the production of inflammatory mediators, suppressed pulmonary inflammation, and mitigated lung tissue damage. Antibiotic-loaded GRb1@LEVS-cRGD effectively reached the infection sites and exhibited both anti-inflammatory and synergistic bactericidal effects. (c) Cytoprotective Capacity of GRb1@LEVs-cRGD in inflammation.

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: Construct, Derivative Assay, Membrane, In Vivo, Infection

Synthesis and characterization of GRb1@LEVS-cRGD. (a) Transmission electron microscopy (TEM) images of lemon‐derived EVs (LEVs), GRb1, GRb1@LEVs, and GRb1@LEVs-cRGD. (b) Fluorescence emission spectra of GRb1@LEVs. LEVs was doped with DiD and DiI, and then mixed with increasing amount of GRb1. (c) CLSM image of GRb1@LEVs prepared from DiO-labeled GRb1 (green) and DiD-labeled LEVs (red). (d) CLSM image of GRb1@LEVs-cRGD prepared from Chol-PEG 2000 -cRGD-FITC (green) and DiD-LEVs (red). (e) Hydrodynamic size distribution of nanoparticles determined by DLS. f) Zeta potentials of LEVs, GRb1, GRb1@LEVs, and GRb1@LEVs-cRGD (n = 3). (g-h) The stability on size (g) and zeta potential (h) of GRb1@LEVs-cRGD in PBS or PBS containing 10% FBS medium for 5 weeks (n = 3). (i) Schematic illustration of antibiotics remote loading into vesicles. (j) TIG loading yield at different cholesterol inputs (n = 3). (k) Loading yield at different TIG input (n = 3).

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: Synthesis and characterization of GRb1@LEVS-cRGD. (a) Transmission electron microscopy (TEM) images of lemon‐derived EVs (LEVs), GRb1, GRb1@LEVs, and GRb1@LEVs-cRGD. (b) Fluorescence emission spectra of GRb1@LEVs. LEVs was doped with DiD and DiI, and then mixed with increasing amount of GRb1. (c) CLSM image of GRb1@LEVs prepared from DiO-labeled GRb1 (green) and DiD-labeled LEVs (red). (d) CLSM image of GRb1@LEVs-cRGD prepared from Chol-PEG 2000 -cRGD-FITC (green) and DiD-LEVs (red). (e) Hydrodynamic size distribution of nanoparticles determined by DLS. f) Zeta potentials of LEVs, GRb1, GRb1@LEVs, and GRb1@LEVs-cRGD (n = 3). (g-h) The stability on size (g) and zeta potential (h) of GRb1@LEVs-cRGD in PBS or PBS containing 10% FBS medium for 5 weeks (n = 3). (i) Schematic illustration of antibiotics remote loading into vesicles. (j) TIG loading yield at different cholesterol inputs (n = 3). (k) Loading yield at different TIG input (n = 3).

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: Transmission Assay, Electron Microscopy, Derivative Assay, Fluorescence, Labeling, Zeta Potential Analyzer

Good biocompatibility of GRb1@LEVs-cRGD in vitro and in vivo . (a-c) CCK-8 assays in RAW264.7, MLE-12 and HUVEC cells, respectively (n = 3). (d) Live/dead cell staining in RAW264.7, MLE-12 and HUVEC cells. Green, Calcein AM staining for live cells. Red, propidium iodide staining for dead cells (n = 3). (e) Cell skeleton staining in HUVECs. Green, FITC phalloidine. Blue, DAPI. (f) Blood routine and biochemical indexes ( n = 3). (g) Representative TUNEL staining of lung tissues from GRb1@LEVs-cRGD and control groups (n = 3). (h) Histopathological examination by H&E staining of major organs (n = 3).

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: Good biocompatibility of GRb1@LEVs-cRGD in vitro and in vivo . (a-c) CCK-8 assays in RAW264.7, MLE-12 and HUVEC cells, respectively (n = 3). (d) Live/dead cell staining in RAW264.7, MLE-12 and HUVEC cells. Green, Calcein AM staining for live cells. Red, propidium iodide staining for dead cells (n = 3). (e) Cell skeleton staining in HUVECs. Green, FITC phalloidine. Blue, DAPI. (f) Blood routine and biochemical indexes ( n = 3). (g) Representative TUNEL staining of lung tissues from GRb1@LEVs-cRGD and control groups (n = 3). (h) Histopathological examination by H&E staining of major organs (n = 3).

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: In Vitro, In Vivo, CCK-8 Assay, Staining, TUNEL Assay, Control

In vitro and in vivo targeted delivery of GRb1@LEVs-cRGD (a-b) confocal microscopy images of the uptake of nanoparticles by RAW 264.7 (a) and HUVEC cells (b) under inflammation and physiological conditions. (c-d) The corresponding quantitative analysis in RAW 264.7 (c) and HUVEC cells (d), respectively (n = 5). (e-f) IVIS images showing the fluorescent distribution in the heart, liver, spleen, lung, and kidney at 2 h after injection of Cy5.5-labeled vesicles (e), along with the corresponding quantification of mean fluorescent intensity (f) (n = 3). (g) Corresponding fluorescence intensity quantification of lung at different times (n = 3). (h) Uptake distribution of GRb1@LEVs-cRGD in various lung cell types (n = 3).

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: In vitro and in vivo targeted delivery of GRb1@LEVs-cRGD (a-b) confocal microscopy images of the uptake of nanoparticles by RAW 264.7 (a) and HUVEC cells (b) under inflammation and physiological conditions. (c-d) The corresponding quantitative analysis in RAW 264.7 (c) and HUVEC cells (d), respectively (n = 5). (e-f) IVIS images showing the fluorescent distribution in the heart, liver, spleen, lung, and kidney at 2 h after injection of Cy5.5-labeled vesicles (e), along with the corresponding quantification of mean fluorescent intensity (f) (n = 3). (g) Corresponding fluorescence intensity quantification of lung at different times (n = 3). (h) Uptake distribution of GRb1@LEVs-cRGD in various lung cell types (n = 3).

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: In Vitro, In Vivo, Confocal Microscopy, Injection, Labeling, Fluorescence

The anti-inflammatory effect of the nanoparticles in vitro (a) The proportion of CD86 M1 and CD206 M2 in RAW264.7 cells by flow cytometry. (b-c) Level of inflammatory cytokines IL-6, TNF-α and IL-10 in LPS-stimulated RAW 264.7 cells (b) and MH-S cells (c) after different treatments (n = 5). (d-e) NF-κB p65 nuclear translocation observed by CLSM (n = 5). ①control group; ② PBS treated group; ③ LEVs treated group; ④ GRb1 treated group; ⑤ GRb1@LEVs treated group; ⑥ GRb1@LEVs-cRGD treated group. (f) The protein expressions of key members in the NF-κB pathway by Western blot, including the phosphorylated (p-p65) and basal NF-κB p65, p-IκBα, and IκBα (n = 3). (g) Heat map showing the hierarchical clustering results of the DEGs detected between LPS group and LPS treated with GRb1@LEVs-cRGD group. DEGs were identified based on a fold change greater than 1.5 and an adjusted P-value less than 0.05. (g) Gene Ontology (GO) term enrichment analysis was performed, and the top 30 significantly enriched GO terms were selected based on an FDR <0.05. (h) Top 20 enriched pathways identified using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs in cells triggered with LPS. (i-j) Gene Set Enrichment Analysis (GSEA) images. (l) Schematic illustration of the mechanism in the reprogramming of RAW 264.7 cells by GRb1@LEVs-cRGD.

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: The anti-inflammatory effect of the nanoparticles in vitro (a) The proportion of CD86 M1 and CD206 M2 in RAW264.7 cells by flow cytometry. (b-c) Level of inflammatory cytokines IL-6, TNF-α and IL-10 in LPS-stimulated RAW 264.7 cells (b) and MH-S cells (c) after different treatments (n = 5). (d-e) NF-κB p65 nuclear translocation observed by CLSM (n = 5). ①control group; ② PBS treated group; ③ LEVs treated group; ④ GRb1 treated group; ⑤ GRb1@LEVs treated group; ⑥ GRb1@LEVs-cRGD treated group. (f) The protein expressions of key members in the NF-κB pathway by Western blot, including the phosphorylated (p-p65) and basal NF-κB p65, p-IκBα, and IκBα (n = 3). (g) Heat map showing the hierarchical clustering results of the DEGs detected between LPS group and LPS treated with GRb1@LEVs-cRGD group. DEGs were identified based on a fold change greater than 1.5 and an adjusted P-value less than 0.05. (g) Gene Ontology (GO) term enrichment analysis was performed, and the top 30 significantly enriched GO terms were selected based on an FDR <0.05. (h) Top 20 enriched pathways identified using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of DEGs in cells triggered with LPS. (i-j) Gene Set Enrichment Analysis (GSEA) images. (l) Schematic illustration of the mechanism in the reprogramming of RAW 264.7 cells by GRb1@LEVs-cRGD.

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: In Vitro, Flow Cytometry, Translocation Assay, Western Blot

Cytoprotective Capacity of GRb1@LEVs-cRGD in inflammation. (a-b) Cell viability of MLE-12 (a) and HUVEC cells (b) under different treatment conditions (n = 5). (c-d) Caspase 3 activity of MLE-12 (c) and HUVEC (d) cells under different treatment conditions (n = 5). (e-g) Flow cytometry analysis using Annexin V/PI staining (e) and corresponding quantitative comparison of MLE-12 cells (f) and HUVEC cells (g) exposed to different treatments ( n = 3). (h-i) Fluorescence images of JC-1-stained MLE-12 cells after different treatments ( n = 5). (j) The expression pattern of ZO-1 protein by immunofluorescent staining in HUVECs (n = 5). (k-l) Fluorescence images (k) of TUNEL staining RAW 264.7 cells after different treatments ( n = 5) and corresponding quantification (l) (n = 5).

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: Cytoprotective Capacity of GRb1@LEVs-cRGD in inflammation. (a-b) Cell viability of MLE-12 (a) and HUVEC cells (b) under different treatment conditions (n = 5). (c-d) Caspase 3 activity of MLE-12 (c) and HUVEC (d) cells under different treatment conditions (n = 5). (e-g) Flow cytometry analysis using Annexin V/PI staining (e) and corresponding quantitative comparison of MLE-12 cells (f) and HUVEC cells (g) exposed to different treatments ( n = 3). (h-i) Fluorescence images of JC-1-stained MLE-12 cells after different treatments ( n = 5). (j) The expression pattern of ZO-1 protein by immunofluorescent staining in HUVECs (n = 5). (k-l) Fluorescence images (k) of TUNEL staining RAW 264.7 cells after different treatments ( n = 5) and corresponding quantification (l) (n = 5).

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: Activity Assay, Flow Cytometry, Staining, Comparison, Fluorescence, Expressing, TUNEL Assay

GRb1@LEVs-cRGD alleviated LPS-induced lung injury and inflammatory responses in the lung. (a) Schematic illustration of animal experimental design. (b-d) lung wet/dry ratio (b), levels of protein (c), total cell number (d) in BALF in LPS induced ALI mice treated with PBS, LEVs, GRb1, GRb1@LEVs, GRb1@LEVs-cRGD (n = 5). (e-h) Level of IL-6 and TNF-α in BALF (e) and serum (h) of mice after different treatments (n = 5). (i-j) Representative H&E images of lungs after different treatments (i) and the corresponding analysis of lung injury score (j) (n = 5). (k) Lung tissue analysis TUNEL staining in each group (n = 5). (l-n) The distribution of tight junction proteins, ZO-1 and VE-Cadherin, by immunofluorescent staining in lung tissues and corresponding quantification.

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: GRb1@LEVs-cRGD alleviated LPS-induced lung injury and inflammatory responses in the lung. (a) Schematic illustration of animal experimental design. (b-d) lung wet/dry ratio (b), levels of protein (c), total cell number (d) in BALF in LPS induced ALI mice treated with PBS, LEVs, GRb1, GRb1@LEVs, GRb1@LEVs-cRGD (n = 5). (e-h) Level of IL-6 and TNF-α in BALF (e) and serum (h) of mice after different treatments (n = 5). (i-j) Representative H&E images of lungs after different treatments (i) and the corresponding analysis of lung injury score (j) (n = 5). (k) Lung tissue analysis TUNEL staining in each group (n = 5). (l-n) The distribution of tight junction proteins, ZO-1 and VE-Cadherin, by immunofluorescent staining in lung tissues and corresponding quantification.

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: TUNEL Assay, Staining

TIG/GRb1@LEVs-cRGD alleviated Kp NDM-induced lung injury and inflammatory responses in the lung. (a) Experimental design of in vivo assessment using a Kp NDM-induced model. (b) Growth curves of KP NDM co-incubated with various preparations (n = 3). (c) Corresponding quantification of bacterial load in lung tissue homogenate (n = 5). (d-e) Lung wet/dry ratio (d) and levels of protein (e) in Kp NDM-induced ALI mice treated with PBS, TIG, TIG/GRb1@LEVs-cRGD and negative control (n = 5). (f-h) IL-6 (f) and TNF-α (g) IL-1β (h) of BALF in above groups (n = 5). (i-j) Representative H&E images of the lung after different treatments (i) and corresponding lung injury score analysis (j) (n = 5). (k-p) Immunofluorescence staining images of IL-6 (k) and corresponding quantitative analysis (n), TNF-α (l) and corresponding quantitative analysis (o), IL-1β(m) and corresponding quantitative analysis (p) (n = 5).

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: TIG/GRb1@LEVs-cRGD alleviated Kp NDM-induced lung injury and inflammatory responses in the lung. (a) Experimental design of in vivo assessment using a Kp NDM-induced model. (b) Growth curves of KP NDM co-incubated with various preparations (n = 3). (c) Corresponding quantification of bacterial load in lung tissue homogenate (n = 5). (d-e) Lung wet/dry ratio (d) and levels of protein (e) in Kp NDM-induced ALI mice treated with PBS, TIG, TIG/GRb1@LEVs-cRGD and negative control (n = 5). (f-h) IL-6 (f) and TNF-α (g) IL-1β (h) of BALF in above groups (n = 5). (i-j) Representative H&E images of the lung after different treatments (i) and corresponding lung injury score analysis (j) (n = 5). (k-p) Immunofluorescence staining images of IL-6 (k) and corresponding quantitative analysis (n), TNF-α (l) and corresponding quantitative analysis (o), IL-1β(m) and corresponding quantitative analysis (p) (n = 5).

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: In Vivo, Incubation, Negative Control, Immunofluorescence, Staining

Vanc/GRb1@LEVs-cRGD alleviated MRSA-induced lung injury and inflammatory responses in the lung. (a) Experimental design of in vivo assessment using a MRSA-induced model. (b) Growth curves of MRSA co-incubated with various preparations (n = 3). (c) Corresponding quantification of bacterial load in lung tissue homogenate (n = 5). (d-e) Lung wet/dry ratio (d) and levels of protein (e) in MRSA-induced ALI mice treated with PBS, Vanc, Vanc/GRb1@LEVs-cRGD and negative control (n = 5). (f-h) IL-6 (f) and TNF-α (g) IL-1β (h) of BALF in above groups (n = 5). (i-j) Representative H&E images of the lung after different treatments (i) and corresponding lung injury score analysis (j) (n = 5). (k-p) Immunofluorescence staining images of IL-6 (k) and corresponding quantitative analysis (n), TNF-α (l) and corresponding quantitative analysis (o), IL-1β (m) and corresponding quantitative analysis (p) (n = 5).

Journal: Bioactive Materials

Article Title: A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury

doi: 10.1016/j.bioactmat.2026.03.033

Figure Lengend Snippet: Vanc/GRb1@LEVs-cRGD alleviated MRSA-induced lung injury and inflammatory responses in the lung. (a) Experimental design of in vivo assessment using a MRSA-induced model. (b) Growth curves of MRSA co-incubated with various preparations (n = 3). (c) Corresponding quantification of bacterial load in lung tissue homogenate (n = 5). (d-e) Lung wet/dry ratio (d) and levels of protein (e) in MRSA-induced ALI mice treated with PBS, Vanc, Vanc/GRb1@LEVs-cRGD and negative control (n = 5). (f-h) IL-6 (f) and TNF-α (g) IL-1β (h) of BALF in above groups (n = 5). (i-j) Representative H&E images of the lung after different treatments (i) and corresponding lung injury score analysis (j) (n = 5). (k-p) Immunofluorescence staining images of IL-6 (k) and corresponding quantitative analysis (n), TNF-α (l) and corresponding quantitative analysis (o), IL-1β (m) and corresponding quantitative analysis (p) (n = 5).

Article Snippet: Ginsenoside Rb1 and Tigecycline (TIG) were supplied by Shanghai Yuanye Bio-Technology Co., Ltd (China).

Techniques: In Vivo, Incubation, Negative Control, Immunofluorescence, Staining

Grb1 significantly reduces inflammatory levels and improves survival outcome in CLP rats. ( A ) Identification of MTHFD2 drug targets using molecular docking techniques. ( B ) mRNA expression analysis of MTHFD2 in control, CLP, and CLP+Grb1 groups (n = 6). ( C , D ) Survival analysis of control, CLP, and CLP+Grb1 groups (n = 6). ( E – G ) Quantitative analysis of IL-1β, IL-6, and TNF-α levels in control, CLP, and CLP+Grb1 groups (n = 6). ( H ) Wet/dry ratio analysis of the left lung (n = 6). ( I , J ) Quantitative analysis of creatinine and ALT levels in CLP and CLP+Grb1 groups (n = 6). Data are presented as mean ± SD; statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Journal: Scientific Reports

Article Title: Multi-omics analysis reveals that ginsenoside Rb1 improves prognostic outcomes in sepsis by modulating mitochondrial metabolism MTHFD2 targets

doi: 10.1038/s41598-026-37362-9

Figure Lengend Snippet: Grb1 significantly reduces inflammatory levels and improves survival outcome in CLP rats. ( A ) Identification of MTHFD2 drug targets using molecular docking techniques. ( B ) mRNA expression analysis of MTHFD2 in control, CLP, and CLP+Grb1 groups (n = 6). ( C , D ) Survival analysis of control, CLP, and CLP+Grb1 groups (n = 6). ( E – G ) Quantitative analysis of IL-1β, IL-6, and TNF-α levels in control, CLP, and CLP+Grb1 groups (n = 6). ( H ) Wet/dry ratio analysis of the left lung (n = 6). ( I , J ) Quantitative analysis of creatinine and ALT levels in CLP and CLP+Grb1 groups (n = 6). Data are presented as mean ± SD; statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Rats were randomly assigned to three groups: Sham, CLP, and Ginsenoside Rb1 (Grb1)-treated CLP (CLP+Grb1) group (HY-N0039, MedChemExpress).

Techniques: Expressing, Control

Review

Structured Review

Images

Similar Products

Image Search Results